QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments

- Cloud application marks another milestone for QIAGEN by adding guidance for customers along the entire product portfolio

- Application covers seamless portfolio transition from “wet lab” benchtop products through to “dry lab” digital applications

- The Workflow Configurator allows customers to quickly find the best workflows tailored to their needs, which they can conveniently order, save or share.

Germantown, Maryland, and Hilden, Germany, July 07, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best solutions to optimize their experiments.

Customers simply choose their application, biological starting material, analyte and analysis type. In seconds, the configurator sorts through hundreds of potential products to find the most suitable workflow and associated products. The Workflow Configurator – which is available at https://www.qiagen.com/workflow-configurator/workflows – also offers direct purchase and sales support.

This cloud-based application marks another milestone on QIAGEN’s path to digitalizing its product range. It allows customers to choose from a variety of products per workflow step, as well as save, share and purchase their bespoke product configuration.

“QIAGEN knows discoveries take careful workflow planning and optimization, and we design our solutions with this in mind. The QIAGEN Workflow Configurator is an uniquely useful digital solution that makes researchers’ day-to-day laboratory routine more efficient and productive, even with the most challenging samples,” said Thomas Schweins, Senior Vice President of the Business Area Life Sciences of QIAGEN. “Digital tools are of tremendous importance for the Life Sciences industry. QIAGEN is also investing in multiple other industry leading activities such as QIAGEN Digital Insights – which offers unique integrated data assets combined with deep analytical skills - or GeneGlobe – the leading gene-design, customization and analysis platform.”

Researchers in life sciences drive their experiments from Sample to Insight to test new theories or probe areas no one has looked at before. As a result, they need adaptable workflows and will benefit from the Workflow Configurator’s ability to identify alternative lab products and many ways to integrate them with existing laboratory equipment.

The Workflow Configurator guides customers effortlessly through the QIAGEN portfolio and is integrated with My QIAGEN, the self-service customer portal of QIAGEN, and QIAGEN’s Web Shop for a seamless experience that allows researchers to manage their various laboratory-related activities on one easy-to-use platform.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and

other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2021, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

QIAGEN

Investor Relations		**Public Relations**	
John Gilardi	+49 2103 29 11711	Thomas Theuringer	+49 2103 29 11826
Phoebe Loh	+49 2103 29 11457	Robert Reitze	+49 2103 29 11676
e-mail: ir@QIAGEN.com		e-mail: pr@QIAGEN.com	

Source: QIAGEN N.V.

Category: Corporate